Another investor opposes Somalogic merger

Advisory firm urges shareholders approval

BOULDER — Investment firm Tikvah Management LLC plans to oppose SomaLogic Inc.’s (Nasdaq: SLGC) planned $1 billion merger with California-based Standard BioTools Inc. (Nasdaq: LAB), making Tikvah the second major investor to stake out a position against the deal in the last week or so. 

Meanwhile, SomaLogic, is touting support of the merger from Institutional Shareholder Services Inc., a proxy advisory firm that provides guidance for institutional investors such as mutual or pension funds.

Tikvah, which claims that it holds voting rights for 5.9 million SomaLogic shares, or 3.1% of the company’s outstanding shares, said that…